Advertisement

Journal of Neural Transmission

, Volume 126, Issue 1, pp 65–85 | Cite as

Clinical implications of APOE genotyping for late-onset Alzheimer’s disease (LOAD) risk estimation: a review of the literature

  • Victoria S. Marshe
  • Ilona Gorbovskaya
  • Sarah Kanji
  • Maxine Kish
  • Daniel J. MüllerEmail author
Psychiatry and Preclinical Psychiatric Studies - Review Article
  • 132 Downloads

Abstract

Alzheimer’s disease is a genetically complex neurodegenerative disorder representing the leading cause of dementia. Advances in personal genomics are increasing the public uptake of genetic susceptibility testing for complex diseases such as late-onset Alzheimer’s disease (LOAD). For LOAD, the discovery of the major risk ε4 allele of the APOE gene has prompted a debate on the ethics and utility of presymptomatic (i.e., predictive) testing. Although the mechanistic contribution of APOE to disease onset remains uncertain, presymptomatic genetic testing provides a relative risk of developing LOAD. Presymptomatic testing for complex disorders, such as LOAD is much less conclusive than early-onset Alzheimer’s disease (EOAD) which follows a Mendelian inheritance pattern. Given the lack of preventive strategies available for EOAD or LOAD, APOE genotyping offers limited clinical utility, thus, raising ethical and practical questions. We conducted a systematic search of five electronic databases or primary studies published during January 2008–January 2018 which investigated practical and ethical issues of presymptomatic APOE genotyping for LOAD risk estimation. We identified 31 articles which suggested that APOE genotyping for LOAD susceptibility provides potential benefits to at-risk patients and can guide changes in positive health-related behaviors. However, other individuals may experience test-related anxiety, depression and psychological distress. Future research should focus on developing an integrated risk assessment tool to enhance the utility of APOE genotyping. Furthermore, empirical research is required to understand actual psychological and social implications associated with testing.

Keywords

Genetic testing Direct-to-consumer APOE Alzheimer’s disease Ethics 

References

  1. Almeling R, Gadarian SK (2014) Reacting to genetic risk: an experimental survey of life between health and disease. J Health Soc Behav 55:482–503Google Scholar
  2. Ashida S, Koehly LM, Roberts JS et al (2009) Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer’s disease. J Health Commun 14:768–784Google Scholar
  3. Ashida S, Koehly LM, Roberts JS et al (2010) The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet 18:1296–1301Google Scholar
  4. Bertram L, McQueen MB, Mullin K et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17–23Google Scholar
  5. Besser AG, Sanderson SC, Roberts JS et al (2015) Factors affecting recall of different types of personal genetic information about Alzheimer’s disease risk: the REVEAL study. Public Health Genom 18:78–86Google Scholar
  6. Bird TD (2008) Genetic aspects of Alzheimer disease. Genet Med 10:231–239Google Scholar
  7. Blacker D, Haines JL, Rodes L et al (1997) ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. Neurology 48:139–147Google Scholar
  8. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333Google Scholar
  9. Buchhave P, Minthon L, Zetterberg H et al (2012) Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69:98–106Google Scholar
  10. Campos M, Edland SD, Peavy GM (2013) Exploratory study of apolipoprotein E ε4 genotype and risk of Alzheimer’s disease in Mexican Hispanics. J Am Geriatr Soc 61:1038–1040Google Scholar
  11. Caselli RJ, Dueck AC, Osborne D et al (2009) Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 361:255–263Google Scholar
  12. Caselli RJ, Langbaum J, Marchant GE et al (2014) Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc 89:1389–1396Google Scholar
  13. Caselli RJ, Marchant GE, Hunt KS et al (2015) Predictive testing for Alzheimer’s disease: suicidal ideation in healthy participants. Alzheimer Dis Assoc Disord 29:252–254Google Scholar
  14. Cassidy MR, Roberts JS, Bird TD et al (2008) Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer’s disease. Alzheimers Dement 4:406–413Google Scholar
  15. Cervilla J, Prince M, Joels S et al (2004) Premorbid cognitive testing predicts the onset of dementia and Alzheimer’s disease better than and independently of APOE genotype. J Neurol Neurosurg Psychiatry 75:1100–1106Google Scholar
  16. Chao S, Roberts JS, Marteau TM et al (2008) Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord 22:94–97Google Scholar
  17. Chen C-H, Mizuno T, Elston R et al (2010) A comparative study to screen dementia and APOE genotypes in an ageing East African population. Neurobiol Aging 31:732–740Google Scholar
  18. Christensen KD, Roberts JS, Royal CDM et al (2008) Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med 10:207–214Google Scholar
  19. Christensen KD, Roberts JS, Uhlmann WR, Green RC (2011) Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med 13:409–414Google Scholar
  20. Christensen KD, Roberts JS, Zikmund-Fisher BJ et al (2015) Associations between self-referral and health behavior responses to genetic risk information. Genome Med 7:10Google Scholar
  21. Christensen KD, Roberts JS, Whitehouse PJ et al (2016) Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease: a randomized trial. Ann Intern Med 164:155–163Google Scholar
  22. Davis DS (2014) Alzheimer disease and pre-emptive suicide. J Med Ethics 40:543–549Google Scholar
  23. Dresser R (2014) Pre-emptive suicide, precedent autonomy and preclinical Alzheimer disease. J Med Ethics 40:550–551Google Scholar
  24. Durnin M, Hoy M, Ruse M, Others (2012) Genetic testing and insurance: The complexity of adverse selection. Ethical Perspect 19:123–154Google Scholar
  25. Eisenberg DTA, Kuzawa CW, Hayes MG (2010) Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol 143:100–111Google Scholar
  26. Ekstract M, Holtzman GI, Kim KY et al (2017) Evaluation of a Web-based decision aid for people considering the APOE genetic test for Alzheimer risk. Genet Med 19:676–682Google Scholar
  27. Fanshawe TR, Prevost AT, Roberts JS et al (2008) Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test 12:381–386Google Scholar
  28. Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta-analysis consortium. JAMA 278:1349–1356Google Scholar
  29. Galvin JE, Fu Q, Nguyen JT et al (2008) Psychosocial determinants of intention to screen for Alzheimer’s disease. Alzheimers Dement 4:353–360Google Scholar
  30. Green RC, Roberts JS, Cupples LA et al (2009) Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med 361:245–254Google Scholar
  31. Guan Y, Roter DL, Erby LH et al (2017) Disclosing genetic risk of Alzheimer’s disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927–935Google Scholar
  32. Hercher LS, Caudle M, Griffin J et al (2016) Student-athletes’ views on APOE genotyping for increased risk of poor recovery after a traumatic brain injury. J Genet Couns 25:1267–1275Google Scholar
  33. Hiraki S, Chen CA, Roberts JS et al (2009) Perceptions of familial risk in those seeking a genetic risk assessment for Alzheimer’s disease. J Genet Couns 18:130–136Google Scholar
  34. Huang M-Y, Huston SA, Perri M (2014) Consumer preferences for the predictive genetic test for Alzheimer disease. J Genet Couns 23:172–178Google Scholar
  35. Humpel C (2011) Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol 29:26–32Google Scholar
  36. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer’s disease. Neuron 63:287–303Google Scholar
  37. Klitzman R, Abbate KJ, Chung WK et al (2014) Psychiatrists’ views of the genetic bases of mental disorders and behavioral traits and their use of genetic tests. J Nerv Ment Dis 202:530–538Google Scholar
  38. Kopits IM, Chen C, Roberts JS et al (2011) Willingness to pay for genetic testing for Alzheimer’s disease: a measure of personal utility. Genet Test Mol Biomark 15:871–875Google Scholar
  39. Lambert JC, Ibrahim-Verbaas CA, Harold D et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–1458Google Scholar
  40. Lerner B, Roberts JS, Shwartz M et al (2014) Distinct communication patterns during genetic counseling for late-onset Alzheimer’s risk assessment. Patient Educ Couns 94:170–179Google Scholar
  41. Lineweaver TT, Bondi MW, Galasko D, Salmon DP (2014) Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry 171:201–208Google Scholar
  42. Linnenbringer E, Roberts JS, Hiraki S et al (2010) “I know what you told me, but this is what I think:” perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med 12:219–227Google Scholar
  43. Liu C-C, Liu C-C, Kanekiyo T et al (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118Google Scholar
  44. Messner DA (2011) Informed choice in direct-to-consumer genetic testing for Alzheimer and other diseases: lessons from two cases. New Genet Soc 30:59–72Google Scholar
  45. Neumann PJ, Cohen JT, Hammitt JK et al (2012) Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 21:238–251Google Scholar
  46. Nyholt DR, Yu C-E, Visscher PM (2009) On Jim Watson’s APOE status: genetic information is hard to hide. Eur J Hum Genet 17:147–149Google Scholar
  47. Ostergren JE, Gornick MC, Carere DA et al (2015) How well do customers of direct-to-consumer personal genomic testing services comprehend genetic test results? Findings from the impact of personal genomics study. Public Health Genom 18:216–224Google Scholar
  48. Paniagua CT, Taylor RE (2008) The cultural lens of genomics. OJIN Online J Issues Nurs 13(1):Manuscript 5.  https://doi.org/10.3912/OJIN.Vol13No01Man05 Google Scholar
  49. Patterson C, Feightner JW, Garcia A et al (2008) Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178:548–556Google Scholar
  50. Peters KR, Lynn Beattie B, Feldman HH, Illes J (2013) A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. Prog Neurobiol 110:114–123Google Scholar
  51. Prince M, Bryce R, Albanese E et al (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9:63–75.e2Google Scholar
  52. Qian J, Wolters FJ, Beiser A et al (2017) APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med 14:e1002254Google Scholar
  53. Roberts JS, Gornick MC, Carere DA et al (2017) Direct-to-consumer genetic testing: user motivations, decision making, and perceived utility of results. Public Health Genom 20:36–45Google Scholar
  54. Sando SB, Melquist S, Cannon A et al (2008) APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer’s disease; a case control study from central Norway. BMC Neurol 8:9Google Scholar
  55. Schlesinger D, Grinberg LT, Alba JG et al (2011) African ancestry protects against Alzheimer’s disease-related neuropathology. Mol Psychiatry 18:79Google Scholar
  56. Sherman K, Shaw L-K, Champion K et al (2015) The effect of disease risk probability and disease type on interest in clinic-based versus direct-to-consumer genetic testing services. J Behav Med 38:706–714Google Scholar
  57. Taylor DH Jr, Cook-Deegan RM, Hiraki S et al (2010) Genetic testing for Alzheimer’s and long-term care insurance. Health Aff 29:102–108Google Scholar
  58. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18:421–430Google Scholar
  59. Vernarelli JA, Roberts JS, Hiraki S et al (2010) Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr 91:1402–1407Google Scholar
  60. Wang S-C, Oelze B, Schumacher A (2008) Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS One 3:e2698Google Scholar
  61. Wikler EM, Blendon RJ, Benson JM (2013) Would you want to know? Public attitudes on early diagnostic testing for Alzheimer’s disease. Alzheimers Res Ther 5:43Google Scholar
  62. Zeng Y, Hughes CL, Lewis MA et al (2011) Interactions between life stress factors and carrying the APOE4 allele adversely impact self-reported health in old adults. J Gerontol A Biol Sci Med Sci 66A:1054–1061Google Scholar
  63. Zgheib NK, Arawi T, Mahfouz RA, Sabra R (2011) Attitudes of health care professionals toward pharmacogenetic testing. Mol Diagn Ther 15:115–122Google Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Victoria S. Marshe
    • 1
    • 2
  • Ilona Gorbovskaya
    • 2
  • Sarah Kanji
    • 2
    • 3
  • Maxine Kish
    • 2
    • 4
  • Daniel J. Müller
    • 1
    • 2
    • 5
    Email author
  1. 1.Institute of Medical ScienceUniversity of TorontoTorontoCanada
  2. 2.Pharmacogenetics Research Clinic, Campbell Family Mental Health Research InstituteCentre for Addiction and Mental HealthTorontoCanada
  3. 3.Faculty of MedicineUniversity of TorontoTorontoCanada
  4. 4.Faculty of MedicineQueen’s UniversityKingstonCanada
  5. 5.Department of PsychiatryUniversity of TorontoTorontoCanada

Personalised recommendations